EGFR and non-small cell lung carcinoma: The introduction of tyrosine kinase inhibitors in the treatment of EGFR-mutated NSCLC significantly improved the survival time of patients with locoregionally advanced and metastatic disease, and it has shown great potential in those who undergo surgical resection of early-stage NSCLC.